Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab for vulvar squamous cell carcinoma
NL-OMON53949Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in vulvar squamous cell carcinoma (VSCC), sponsored by Leiden University Medical Center. Primary endpoint: Objective change in tumor size at surgery. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON53949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53949.